Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyl Sulfoxide SCHEMBL4968915 | 1.00 | — | — | |
| Dimethyl Sulfoxide SCHEMBL2856303 | 0.82 | — | — | |
| Dimethyl Sulfoxide SCHEMBL59 | 0.82 | — | — | |
| Dimethyl Sulfoxide SCHEMBL16720928 | 0.82 | — | — | |
| Dimethyl Sulfoxide SCHEMBL3409 | 0.82 | — | — | |
| Dimethyl Sulfoxide SCHEMBL14248079 | 0.82 | — | — | |
| Dimethyl Sulfoxide SCHEMBL17141374 | 0.82 | — | — | |
| Dimethyl Sulfoxide SCHEMBL23457363 | 0.76 | — | — | |
| Dimethyl Sulfoxide SCHEMBL10337084 | 0.76 | — | — | |
| Dimethyl Sulfoxide SCHEMBL7933303 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210694-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4164634-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2021257353-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-2323734-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | Schering Corporation (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2257546-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | Schering Corporation (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010042475-A1 | SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010017120-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009105504-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| EP-1945626-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1940850-A2 | FUSED TETRACYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007038209-A2 | FUSED TETRACYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007024944-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |